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The wide spread of infectious diseases have provoked the scientists to develop new types of vaccines.
Among the different types of vaccines, the recently discovered plasmid DNA vaccines, have gained
tremendous attentions in the last few decades as a modern approach of vaccination. The scientiﬁc in-
terest in plasmid DNA vaccines is attributed to their prominent efﬁcacy as they trigger not only the
cellular immune response but also the humoral immune responses. Moreover, pDNA vaccines are easily
to be stored, shipped and produced. However, the puriﬁcation of the pDNA vaccines is a crucial step in
their production and administration, which is usually conducted by different chromatographic tech-
niques. This review summarizes the most recent chromatographic puriﬁcation methods provided in the
literature during the last ﬁve years following our last review in 2013, including afﬁnity chromatography,
hydrophobic interaction chromatography, ion exchange chromatography, multimodal chromatography,
sample displacement chromatography and miscellaneous chromatographic methods.
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The discovery of vaccines has ameliorated the quality and the
length of man's life. Maladies like measles and rubella turned from
epidemics into well controlled in under few years of the intro-
duction of their vaccines [1]. For instance, the period between 1964
and 1965 witnessed an epidemic spread of rubella, which infected
pregnant mothers causing inborn errors and teratogenicity in their
infants [2]. Thus, more than 20,000 infants were born with heart
diseases, mental retardation and impaired vision and hearing [2].
Similarly, poliomyelitis [3], hepatitis A and B [4], pneumonia [5] and
meningitis [6] brought about major catastrophes during their pre-
vaccine era. Nevertheless, the introduction of the vaccines has
remarkably declined the occurrence, morbidity and mortality of
these illnesses [7].
Vaccines function by artiﬁcial induction of an immune response
against infectious microbes upon introduction of the immunogens
to the human body. Scholars achieved success in developing several
kinds of vaccines as live attenuated vaccines, inactivated vaccines,
subunit vaccines, toxoid vaccines and DNA vaccines [8]. Inactivated
vaccines are prepared by application of physical or chemical means
on the microbes in order to put them to death [9]. The dead mi-
crobes are injected into the human body to urge the immune sys-
tem to generate antibodies against them. These vaccines cannot
replicate and do not require refrigeration or special storage con-
ditions. However, they are very weak and have to be administered
more than one shot. Live attenuated vaccines are another form of
vaccines, where weakened microbes act as immunogens [10]. The
microbes do not cause sickness since they are enervated. Measles,
mumps, and chickenpox vaccines are examples of live attenuated
vaccines. However, there are dreads of mutation of the weakened
microbes into contagious microbes especially with immunocom-
promised patients. Another downside of this kind of vaccines is that
they should be preserved at low temperature, which render them
strenuous to be shipped and stored [10]. Subunit vaccines made up
of parts of the bacterial cell components as cell wall poly-
saccharides. Nevertheless, weak immune response towards these
vaccines, limits their application [10].
DNA vaccination is the use of DNA particles of pathogens to
induce the immunity against certain contagions. It is a novel sort of
vaccination methods [11,12], which was identiﬁed as cellular and
humoral immune responses stimulant. The new vaccination
method became available for clinical trials after just ten years of its
debut [13], and some of DNA vaccines are now available in the
market like West Nile virus vaccine which is used for veterinary
applications [14]. On the other hand, plasmid DNA (pDNA) vaccines
are a subtype of DNA vaccines, where the plasmid encoding certain
protein antigen was extracted from the pathogen cell andtransformed into Escherichia coli (E.coli) [15]. The plasmids replicate
in the E.coli cells in a process called “Up-Stream process”. After that,
a process of downstream is applied to obtain a puriﬁed amount of
plasmids (discussed later) [16]. The puriﬁed plasmids are injected
into the human body and reach the nucleus of human cells by
endosomal trafﬁcking. The transgene (plasmids) utilizes the
cellular transcription machinery to produce the antigen protein,
and this process could remain active for several months. Then, the
synthesized protein activates the immune response through MHC-I
and MHC-II pathways [1].
pDNA vaccines showed signiﬁcant advantages over the tradi-
tional protein and virus-based vaccines. The production of pDNA
only requires a reliable fermentation process and does not need
chicken eggs or other time consuming techniques, which make its
production easier and quicker [15]. Moreover, the stability of pDNA
eases its storage and shipping. The most important advantage of
utilizing pDNA vaccine is its ability to induce not only the anti-
bodies but also the cell mediated components of the immune
system [17]. Thus, pDNA vaccines have paid the attention of
numerous investigators in the last few decades. The number of the
published patents about DNA vaccines was increased from 1 in
1990 to 975 in 2017, according to Sciﬁnder as shown in Fig. 1.
Nevertheless, the immunogenicity of the pDNA vaccines is still a
matter of study [15]. The advantages and the disadvantages of
pDNA vaccine are listed in Table 1 [15].
In another approach, plasmid DNA also can be used in gene
therapy. Gene therapy is the utilization of genes as treatment. The
process comprises the transfer of a particular gene into living cells
aiming at ﬁxing an improper gene copy or to insert a new gene to
treat or improve certain disease. The applications of this technique
include treatment of genetic defects, cancer and viral diseases
[15,18]. Many countries permitted the clinical trials of gene therapy
including the United States, Europe and Australia. The ﬁrst gene
therapy success story was in 1990s, when scientists could treat a
type of immune deﬁciency called adenosine deaminase deﬁciency
[19].
In 2013, our research team provided a literature review covering
recent chromatographic procedures for puriﬁcation of pDNA vac-
cines. Here we present an extension covering the novel chro-
matographic methods issued between the period of 2013e2017
including; afﬁnity chromatography [20], anion exchange chroma-
tography [21], multimodal chromatography [22] hydrophobic-
interaction chromatography [15] and size exclusion chromatog-
raphy [23]. In this article, we will discuss and review the most
recent chromatographic methods for puriﬁcation of pDNA that was
accomplished in the last ﬁve years.
Fig. 1. Number of patents in the ﬁeld of pDNA vaccines.
Table 1
The advantages and disadvantages of pDNA vaccines.
Disadvantages Advantages
Low immunogenicity in humans and large animals Cheap in comparison to other protein or micro-organism based
vaccines
Low DNA cellular uptake in high body masses The immune response is long and no need for booster shots
The long immune response may cause inﬂammation or production of autoantibodies Stimulates higher immune response than the other vaccines
The immune response is limited to the protiens and not to non-protein based antigens like
polysaccharides
High stability and easier in shipping and storage
Potentiality to alter the cell growth control genes Low infection risk
Simply developed and produced.
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Plasmids are self-replicated, tiny, and circular double stranded
DNA molecules detached from the DNA of eukaryotic and pro-
karyotic organisms' cells. A plasmid can carry certain genes that are
essential for the survival of the organism, like antibiotic resistance
genes and genes responsible for synthesis of certain proteins [24].
The plasmids have the ability to transmit from one cell to another
by three mechanisms; transformation, transduction and conjuga-
tion. The size of plasmids is measured by Kilo base unit (Kbp), while
its size can range from 1 to 200 Kbp [24].
The pDNA has ﬁve conformations which are different in size and
speed in electrophoresis, namely; open-circular (oc) pDNA, relaxed
circular pDNA, linear pDNA, supercoiled (sc) pDNA and supercoiled
denatured pDNA [24]. The oc pDNA has one strand and circular in
shape. The relaxed circular pDNA is double stranded but relaxed
due to an enzymatic effect. The linear pDNA is cut double stranded
pDNA which have free ends. Sc pDNA is a dense conformation of
pDNA consists of complete double strandwith the normal twist and
shape. The sc denatured pDNA is similar to sc pDNA but less dense
because of the presence of unpaired regions in the pDNA helix [24].
The ﬁve isoforms are different in charge, size, hydrophobicity and
base exposure. The sc isoform is the one of choice in DNA vacci-
nation and gene therapy due to its outstanding stability and
eminent antigenicity [25]. The supercoiling of the sc isoform in-
creases its base exposure and its charge more than the other iso-
forms [26]. Researchers took advantage of this characteristic in
separation of sc pDNA isoform (discussed later). However, the sc
isoform may convert into oc or linear isoform under certain phys-
ical and chemical procedures, which may affect its puriﬁcation
yield and recovery [27].3. Plasmid manufacturing
3.1. General idea
Production procedures of pDNA must be set upped before
market approval by developing well-studied manufacturing pro-
cesses. Improvement of the production process by further in-
vestigationsmust be taken into account during the production [28].
The production process of pDNAs involves a series of safe and
effective procedures (Fig. 2) that are established and performed for
regular manufacturing of a certain quantity of pDNA. Firstly, cell
banks of the intended pDNA are prepared, as well as the starting
materials are chosen and analysed. After that, the units of cell
culture and downstream processing are speciﬁed, sorted, designed,
and functioned to create a bulk of pDNA [28]. Eventually, ﬁnal
processes must then be implemented to make the reﬁned pDNA
suitable for its deﬁnitive form by taking into account certain as-
pects, like the route of administration, the dosage form, the addi-
tives, the recommended dose, packaging and storage. After this
stage, the product becomes available for pharmaceutical marketing
and clinical trials [28].3.2. Cell culture
After selecting a speciﬁc strain with the target plasmid, cloning
is implemented into E.coli cell. This is followed by the promotion of
pDNA replication by fermentation held to provide a cell bank of the
plasmid containing cells [29]. Certain measures are taken to mini-
mize the probability of recombination and degradation of pDNA.
The growth conditions of the cells should be carefully selected and
optimized; such as the growth media, bioreactor operating
Fig. 2. General idea about the plasmid DNA production steps [28].
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yield. At its best conditions, operation may yield up to 2.0 g/L [30].
3.3. Downstream processing
The main aim of the downstream process (Fig. 3) is to obtain the
pDNA in a reasonable purity that meets the pharmaceutical spec-
iﬁcations, and get rid of the other cell impurities like RNA, proteins
and genomic DNA [15]. The whole process could consist of three
stages namely preliminary puriﬁcation, intermediate puriﬁcation
and ﬁnal puriﬁcation. In the preliminary puriﬁcation step, the high
density broth of E.coli cells harvested from fermentation step was
collected using different techniques like centrifugation or micro-
ﬁltration. Subsequently, the cells are lysed to liberate the pDNA by
means of lysis techniques, like alkaline lysis or thermal lysis, to take
out the lysates. In the second step, clariﬁcation and pre-puriﬁcation
procedures are taken to decrease the levels of impurities in the
lysates and prepare the pDNA for the ﬁnal puriﬁcation stage [15].
The pre-puriﬁcation step can be performed by means of ultraﬁl-
tration [31], tangential ﬂow ﬁltration [23], precipitation [32],
adsorption [33] or aqueous two-phase systems [34]. The pre-
puriﬁcation step is critical for the production of pDNA vaccines,
but it is not enough to obtain the pDNA vaccine in the desired
purity. Thus, a ﬁnal step must be implemented to compile to the
purity stated by the pharmaceutical regulatory bodies.
3.3.1. Chromatographic puriﬁcation of pDNA
The current progresses in biotechnology have allowed the in-
vestigators to explore and produce complex biomolecules like
pDNA through the application of novel techniques, which might
have the ability to improve the human health care. The puriﬁcation
step is the assessment standard of the entire production process
worldwide because of its importance and cost [25]. Various puri-
ﬁcation procedures can be taken like precipitation [35], ultraﬁl-
tration [31] and aqueous two-phase systems [36]; nevertheless,
liquid chromatography is certainly the most extensively imple-
mented technique [37]. The complex content of the plasmidFig. 3. Strategies for purifying supercoiled plasmid DNA. Pure supercoiled plasmid DNA ca
clariﬁcation and concentration before chromatography [15].containing lysates must be taken into consideration when
exploring a puriﬁcation method of pDNA, because other cell con-
stituents (like RNA, gDNA and proteins) are also present in the
lysate media [38]. The puriﬁcation technique must guarantee at
least 97% purity of the ﬁnal obtained pDNA, with at least 80% sc
pDNA, to comply with the requirements of the regulatory agencies.
According to the Food and Drug Administration (FDA) and the
European Agency for the Evaluation of Medical Products (EMEA),
the pDNA vaccines should not contain more than 1% of gDNA, host
proteins, RNA and endotoxins [38,39]. Thus, the demand for an
efﬁcient pDNA puriﬁcation tool is crucial for the manufacturing of
pDNA based vaccines.
Therefore, many chromatographic methods are utilized solely or
mixed as puriﬁcation techniques of pDNA [15]. The chromato-
graphic puriﬁcation step usually faces plentiful challenges due to
the physiochemical properties resemblances, like size, hydropho-
bicity and charge, between pDNA and the other lysate components,
whichmay complicate the separation process [38]. Accordingly, the
puriﬁcation of pDNA may require more than a single chromato-
graphic step to obtain the desired pDNA purity [23]. Moreover, the
puriﬁcation of pDNA by chromatography may be confronted with
other encounters, like the limited number of the existing stationary
phases that have the capacity and ability to bind to the large bio-
molecules like pDNA [38,40]. Furthermore, soft beads packed col-
umns may be susceptible to wricking as well as mass transfer
difﬁculties. These limitations led the researchers to evolve mono-
lith column for industrial use [41].
Monolith is a single piece of porous solid of notable efﬁcient
continuous homogenous stationary phase layer, which allows high
ﬂow rates and high mass transfer with low back pressure [40].
These properties nominate monolith to be an efﬁcient and rapid
puriﬁcation and analysis tool of large macromolecules such as
pDNA [42,43]. Furthermore, additional supports were developed to
get rid of the diffusion limitation and enhance the dynamic binding
capacity such as absorbents like porous glass beads [44]. Thus,
liquid chromatography is the method of choice for puriﬁcation of
pDNA in large scales due to its superb capacity, recovery andn be obtained by moving directly from cell lysis to chromatography or by performing
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to optimize old chromatographic methods or to acquire new ones,
to separate pDNA in good yield and great purity. Selection of the
type of the chromatographic procedures employed depends on the
nature of the pDNA as well as the other lysate components [25].
3.4. Afﬁnity chromatography
Afﬁnity chromatography is a form of chromatography, usually
used for puriﬁcation of biological mixes depending on highly se-
lective reversible interactions between a ligand loaded onto a
support and a substrate [45]. In general, the more interaction sites
between the ligand and the substrate are, the higher dynamic
binding capacity of the ligand will be, which might contribute to
the whole technique's selectivity, speciﬁcity and efﬁcacy. The
outstanding selectivity and versatility of afﬁnity chromatography,
nominate it to be a meaningful tool for puriﬁcation of several
biological molecules like, pDNA, RNA, DNA and proteins [46]. The
use of afﬁnity chromatography as a selective tool for puriﬁcation of
pDNA from lysates and separate their isoforms (sc and oc) enticed
many researchers in the last few years. Puriﬁcation of pDNA from
lysates is based on the fact that the pDNA bind to afﬁnity ligands
through different styles of bonds and interactions like hydrogen
bonds, ionic bonds, hydrophobic interactions, etc. While the other
lysate components (impurities), like RNA, gDNA, proteins and en-
dotoxins, exert different afﬁnities to the ligands at certain mobile
phase's salt concentration, pH and temperature. Therefore, the
separation of the pDNA isoforms happens as the impurities were
washed out while the pDNA molecules were retained or vice versa
[47,48]. Beyond that, afﬁnity chromatography is not only used for
separation of the pDNA molecules from lysates, but also it effec-
tively isolates the sc and the oc isoforms of pDNAs. The separation
between the oc and sc isoformsmight be related to the difference in
the conformational structures of the two isoforms. The supercoiling
of the sc pDNA contributes to a superior torsional strain of this
isoform, which raises the charge and the base exposure of this
isoform over that of the oc pDNA isoform [26]. These differences
between the sc and the oc isoforms allow the sc isoform to attach to
the ligands with a different afﬁnity than the oc isoform. By passing
an elution system of changeable ionic strengths, separation be-
tween the two isoforms could take place [26].
For instance, in 2012, berenil (an anti-trypanosomal agent used
in veterinary) was immobilized onto Sepharose column for the
separation of pDNA samples of different sizes [pVAX1-LacZ (6.05
Kbp) and pCAMBIA-1303 (12.361 Kbp)], from clariﬁed and non-
clariﬁed E.coli alkaline lysates [49]. Berenil undergoes hydropho-
bic interaction with pDNA owing to its phenyl group, and other
speciﬁc interactions which might explain its high afﬁnity to pDNA.
Clariﬁcation of the lysate was preceded by precipitation with 2M
ammonium sulphate. The puriﬁcation trials were implemented
ﬁrstly on the clariﬁed lysate. After the retention of all lysate com-
ponents with 1.3M of ammonium sulphate in 10mM Tris-HCl
buffer (pH 8.0), pDNA was eluted by descending the salt concen-
tration to 0.55M. The impurities were collected at the last stage of
the previously mentioned elution process. The obtained results
showed satisfactory purity of the separated pDNAs (100%) [49];
however, the environmental hazards and the economical aspect of
the elevated concentration of ammonium sulphate, used in the
mobile phase, are the drawbacks of this approach. Moreover, the
recovery depends on the size of the pDNA, since the recovery of the
small size pVAX1-LacZ was found to be 85%, which is very similar to
a previous afﬁnity chromatography method [50] (84%) and better
yield than a previous HIC method [51]. Nevertheless, the recovery
of the larger size pCAMBIA-1303 is very low (45%). The in-
vestigators explicated that the low recovery of the large sizemolecule might be ascribed to the liability of the large pDNA
molecules during production processes. In order to ease the process
and avoid the hazard of ammonium sulphate used in the clariﬁ-
cation step, trials were implemented on non-clariﬁed E.Coli lysate
through two runs following similar chromatographic conditions.
The purity of the gathered pDNA is quite sufﬁcient, and most of the
RNA was removed; yet, the obtained yield was surprisingly low
(33%). Caramelo-Nunes et al.’s research could not offer a method for
separation between the oc and sc pDNA isoforms [49]. In the same
year, the validation of phenyl-boronic ligands derivatized onto
porous glass beads as a pDNA puriﬁcation stationary phase was
demonstrated. The employed elution system was Milli-Q water
then 1.5M Tris (pH 8.5). Phenyl-boronic column effectively puriﬁed
pVAX-GFP (3.7 kbp) and pVAX1-LacZ (6.1 kbp) with yields of 95.7%
and 94.2% respectively, with reasonable purity [44]. Moreover, the
researchers avoided using ammonium sulphate, which renders the
method environmentally clean. The method offered clean, quick,
facile, reliable and reproducible puriﬁcation process; however, the
scholars did not expose to pDNAmolecules larger than pVAX1-LacZ
[44]. To continue their trials on pDNA puriﬁcation, Caramelo-Nunes
et al. presented a novel method for puriﬁcation of the sc pVAX1-
LacZ isoform from the previously separated mixture of pDNA iso-
forms (ocþsc) from bacterial lysate, using Sepharose support
immobilized with a small DNA ligand: intercalator 3,8-diamino-6-
phenylphenanthridine (DAPP) [52]. The team carried out several
trials to conclude that DAPP-Sepharose has a great afﬁnity to the sc
isoform of pVAX1-LacZ. The best puriﬁcation results were obtained
by employing an elution system of gradient ascending of sodium
chloride concentration (from 0.22M to 0.55M) or descending
ammonium sulphate concentration from (2.1Me0M), in 10mM
acetate buffer pH 5, on Sepharose-DAPP stationary phase. However,
the team favoured the utilization of NaCl in the elution system to
prevent the unfavourable drawbacks of ammonium sulphate. The
chromatographic separation diagram is given in Fig. 4. The sepa-
rated sc isoforms showed superb purity, and the separation is pH
dependent. The use of a low amount of sodium chloride in the
mobile phase keeps the method clean and economic [52]. The
DAPP-Sepharose system was further applied for puriﬁcation of sc
pDNA with different sizes from clariﬁed E. coli lysates using low
amounts of salt in the eluent and providing a high quality sc pDNA
in a single chromatographic step [53].
In another approach, a recent article by Soares et al. [54] com-
bined the previously approved selectivity of arginine ligand to
pDNA [46] with the well-proven eminent mass transfer properties
and superior binding capacity of monolith support [40] for the
isolation of two sc pDNAs of different sizes; sc pHPV-16 E6/E7
(8.702 kbp) and sc pVAX1-LacZ (6.05 kbp), from clariﬁed lysate. The
elution system is based on the employed pre-puriﬁcation tech-
niques. In case of pre-puriﬁcation by Qiagen Kit, the elution system
is two steps; the ﬁrst one is 560mM NaCl in 10 mMTriseHCl and
10mM EDTA buffer (pH 8.0), to remove the lysate impurities, then
2M NaCl at the same buffer to elute the bound sc isoforms. In case
of pre-puriﬁcation by isopropanol/ammonium sulphate/PD10, the
elution system is ascending concentrations of NaCl from 600mM
in10mM TriseHCl/10mM EDTA buffer (pH 8.0) to 740mM then to
1M [54].
The arginine monolith binding capacity was compared to that of
arginine-agarose to evaluate the monolith as a support, and the
ﬁndings proved that arginine monolith possesses superior binding
capacity as shown in Fig. 5 [54]. The use of low concentrations of
salt is an economic advantage of this method. In addition to, the
precluding of ammonium sulphate in the mobile phase, keeps the
method environmentally clean. The puriﬁed larger size sc pHPV-16
E6/E7 demonstrated high purity (>99%); nevertheless, the yield is
extremely low (39%). In contrast, the yield of the smaller sc pVAX1-
Fig. 4. Chromatographic separation of pDNA (25 _L, 600 _g/mL) isoforms on DAPP-Sepharose and agarose gel electrophoresis of the peak fractions. Lane pDNA: sample of pDNA
injected onto the column (mixture of oc and sc isoforms, plus the linear isoform obtained from the enzymatic digestion of the plasmid with Hind III). Lane 1: oc and linear pDNA
fraction collected from peak 1 using as eluent acetate buffer 10mM pH 5 with 0.22M NaCl. Lane 2: sc pDNA fraction collected from peak 2 using acetate buffer 10mM pH 5 with
0.55M NaCl as eluent [52].
Fig. 5. Breakthrough experiments with arginine monolith and conventional arginine-agarose matrix. Flow rate: 1mL/min; feedstock: HPV-16 E6/E7 plasmid solution pre-puriﬁed
with Qiagen kit (0.05mg/mL) was homogenized in 10mM TriseHCl and 10mM EDTA buffer pH 8.0 [54].
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method procedures from the low yield of sc pHPV-16 E6/E7. Thus,
the low yield of sc pHPV-16 E6/E7 might be related to the molecule
properties itself, which might keep it unstable in the production
process [54].
With the intention of developing cost and time effective and
minimal salt consumable method, Caramelo-Nunes et al. utilized
Berenil-Sepharose column yet again for the separation of pVAX1-
LacZ from clariﬁed lysate [55]. A concentration of 0.55M of
ammonium sulphate in 10mM Tris-HCl buffer at pH8.0 was
employed at ﬁrst to elute the pDNA then the salt concentrationwas
lessened to 0M to elute the retained impurities. The lowammonium sulphate concentration used decreases the cost and the
ecological dangers of this method in contrast to their previous in-
vestigations [49,51]. The puriﬁed pDNA was collected with 87%
recovery and more than 99% purity. Moreover, the two-step elution
speeds up the puriﬁcation process of pDNA and saves time and
efforts. However, the method did not prove feasibility in separating
the sc pDNA isoform from the oc/sc mixture [55]. Another study
suggests that methionine could interact with pDNA by strong hy-
drophobic and weak thiophilic interactions which may explain its
great binding capacity with pDNA [56]. Immobilization of L-
methionine onto agarose support was implemented to purify three
sc isoforms of pDNAs of different sizes; HPV-16 E6/E7 plasmid,
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trials were exerted to optimize the elution conditions by changing
the temperature, pH and salt concentration. The best separation
was achieved at 5 C by lowering the ammonium sulphate con-
centration from 2.35 to 1.7M gradually at 10mM Tris-HCl, at pH 8
buffer, then using the buffer alone for the elution of the bound sc
pDNA [56]. The puriﬁed sc pDNA were pure enough; nonetheless,
the recoveries of p53-encoding plasmid, pUC-19, and HPV-16 E6/E7
were very low, 39%, 20% and 30%, respectively. The authors referred
the low recoveries to the plasmid characteristics not to the method
without giving a critical explanation. Furthermore, themethod uses
considerably high concentrations of the costly and non-ecofriendly
ammonium sulphate which are the main drawbacks of this method
[56].
A study on the behavior of nongrafted carbonyldiimidazole
monolithic disks in separation of sc pDNAs of different sizes was
operated by Bicho's team [57]. The team employed their trials on
three different sizes of pDNAs; pcDNA3-based plasmid (14 kbp),
pEGIP (10.292 kbp) and pUC19 (2.686 kbp) in one chromatographicFig. 6. Breakthrough curves of sc pDNA (0.05mg/mL) in CDI disk at room temperature using
pcDNA3-based plasmid (14 kbp), with 2.5M (NH4)2SO4. (B) Plasmid size effect on the DBC,
3M of (NH4)2SO4 concentration. (C) Effect of salt concentration (2.5 and 3M of (NH4)2SOstep using puriﬁed samples of sc and oc isoforms [57]. It was
concluded that, the concentration of ammonium sulphate in the
elution system and the dynamic binding capacity of the column are
inversely proportional to the size of the pDNA as shown in Fig. 6;
since, the larger pDNAs are, the higher their base exposure and the
higher interactions with the stationary system. On the other hand,
the dynamic binding capacity was found to be directly proportional
to ammonium sulphate concentration at low ﬂow rates and low pH
(Fig. 6) [57]. This carbonyldiimidazole monolithic disk was also
applied to purify pDNA suitable for pharmaceutical applications
with high purity level and satisfactory recovery [58]; however, the
elevated concentration of ammonium sulphate used throughout
this method, is not ecologically preferable. Furthermore, a group of
Chinese researchers undertook an investigation to explore the ef-
fect of spacer arm and ligand density of arginine-based beads on
the isolation of a small pDNA molecule; plasmid pET-28a (5.369
kbp) [59]. Elutionwas done using 10mmoL/L Tris-HCl buffer at pH 8
(buffer A) at ﬁrst, then 1.0mol/L NaCl was added to buffer A (buffer
B) to elute the bound pDNA. Another chromatographic procedure1mL/min ﬂow rate. (A) Inﬂuence of large plasmids in the DBC, pEGIP (10.292 kbp), and
pUC19 (2.686 kbp) pVAX-1LacZ (6.05 kbp), and pcDNA3-based plasmid (14 kbp) using
4) and pH (8.0 and 6.0) in the DBC of pcDNA3-based plasmid (14 kbp) [57].
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tion of buffer B employing the same stationary phase. Clariﬁed
samples were injected directly, which eases the process and
shorten the time that may be made in the pre-puriﬁcation pro-
cesses. The presence of electrostatic interaction and hydrogen
bonds between pDNA and the ligand is the reason behind the great
selectivity of arginine [59]. The researchers found that ligand
density and spacer arm are directly proportional to the dynamic
binding capacity, and after trials, the ligand density of the column
of 47mmoL/L might contribute to the best recovery. The puriﬁed sc
pDNA showed reasonable purity 93.8% and good yield (over 80%) at
3mL loading dose [59]. Generally, the research provides eco-
friendly, cheap, rapid and effective procedures, however, the puri-
ﬁcation of higher molecular weight sc pDNAs following these
procedures was not investigated [59]. Once again, another group of
investigators [60] exploited the advantages of monolith as a sup-
port, to combine it with histamine as a trial for improving previous
multimodal chromatographic procedures [61]. The method was
designed to separate large volume of the sc isoform of pVAX1-LacZ
from clariﬁed E.coli lysate (86mL), using ascending NaCl or
descending ammonium sulphate as mobile phases (simple strat-
egy) or by combining the two procedures (combined strategy). The
simple strategy presented better results in terms of selectivity and
purity; however, the combined strategy might be beneﬁcial in case
of column overloading. The best recovery (97%) and purity (99%) of
sc pDNA was secured through the elution system of ascending
concentration of NaCl; 1.70M, 2.08M then 3M NaCl in 50mM
citrate buffer (pH 5.0) [60]. Fortunately, this elution system gave
better results than descending ammonium sulphate. The re-
searchers offered preparative procedures for puriﬁcation of large
volumes of sc pDNA. Moreover, the neatness, simplicity and efﬁ-
ciency of the method qualify it to be an excellent approach for
preparation of pure sc pVAX1-LacZ. Nevertheless, the isolation of
larger sc pDNA molecules was not explored yet [60].
On a similar approach, the same research team carried out
another investigation to explore the mechanisms of histamine and
agmatine ligands, immobilized ontomonolithic disks, in separation
of pVAX1-Lacz sc isoform [62]. Ascending gradient of NaCl in acidic
pH, and descending gradient of ammonium sulphate in alkaline pH
were intended for use as mobile phases. Both elution systems
successfully separated pDNA isoforms; nevertheless the re-
searchers preferred the application of NaCl system to avoid the
environmental hazards of ammonium sulphate. It was proven that
changing in the mobile phase and the pH, changes the interactions
between pDNA with histamine or agmatine. The research group
also proved that, the stability of different sc pDNA molecules of
different sizes: 2.69-kbp pUC19, 6.05-kbp pVAX1-LacZ and 14-kbp
pcDNA3-myc-FLNa S2152A, might be related to the elution system's
ionic strength and pH [62]. Additionally, in order to explore the
versatility of dipeptides as ligands, two dipeptides: L-tyrosine-L-
tyrosine and L-tyrosine-L-arginine, were synthesized and coupled
to epoxide-activated Sepharose support at basic pH and 70 C [32].
Gradient descending ammonium sulphate concentration in 10mM
Tris-HCl and 100mM of HEPES was the mobile phase at different
temperatures (5 C, 10 C and 25 C) for separation of sc pVAX1-
LacZ and sc pcDNA3-FLAG-p53 isoforms [32]. It was demon-
strated that the selectivity and the retention of the sc pVAX1-LacZ
are lower than that of sc pcDNA3-FLAG-p53, although both are
almost of the same size. This difference might be related to the
dissimilarities in the DNA sequences and the structural conﬁgura-
tions of the two sc pDNA isoforms. The temperature was found to
be inversely proportional to the dynamic binding capacity, as the
pDNA molecules demoed higher binding afﬁnity to the dipeptides
ligands with low temperature and vice versa. The research pro-
cedures proved the possibility of puriﬁcation of pDNA using L-tyrosine based-Sepharose; however, the yield and the recovery
were not mentioned. Moreover, the use of ammonium sulphate as
elution system is a controversial [32].
In view of Soares et al. research [54] in 2013, Almeida et al.
implemented a novel trial to improve the recovery of sc HPV-16 E6/
E7 (8.702 kbp) plasmid-based vaccine by optimizing the conditions
of arginine monolith column [26]. The study was based on Com-
posite Central Face through optimization of three factors; the
binding concentration, washing concentration and the pH of the
mobile phase. The elution took place through three steps. The ﬁrst
step is the equilibration step, where NaCl concentration was be-
tween 500 nM and 600 nM in Tris-HCl/EDTA buffer. Then the
washing step, where the salt concentration was raised to between
650 and 750 nM towash RNA, oc pDNA and other impurities. At the
last step, the salt concentration reached 1M at the same buffer in
order to liberate the sc pDNA [26]. The pH ranges from, 7.5 to 8. Low
pH increases the pDNA retention since pKa of arginine is 12. Hence,
at low pH, arginine carries positive charges which interact with sc
pDNA. The recovery was successfully improved from 39% to 83.5%
with 100% purity. Themethod is eco-friendly and can be considered
as a promising approach for the puriﬁcation of large sc pDNA
molecules. Furthermore, the interference of Composite Central Face
technique in designation of chromatographic puriﬁcation method
of pDNA, is a promising approach which might be useful in opti-
mizing the pDNA puriﬁcation in the future [26]. In 2015, the
attractive properties of monolith provoked Amorim et al. to
immobilize L-histidine and its derivatives onto it, for puriﬁcation of
three different sized pDNAs (pVAX1-LacZ, HPV-16 E6/E7, and
pcDNA3) [63]. The separation occurred by decreasing the concen-
tration of ammonium sulphate in the elution system [63]. However,
lowering the ammonium sulphate concentration was needed for
separation of sc pDNAs in the 1-benzyl-L-histidine monolith, due to
the high interactions evolved. The researchers compared the
binding capacity of L-histidine monolith with that of L-histidine
agarose, to ﬁnd the ﬁrst one's is higher by 29 times. The adequate
binding afﬁnity of pDNA to the ligands, especially with HPV16 E6/
E7, allowed the investigation team to purify sc isoforms. However,
the method is solely a screening method, with the authors not
mentioning the yields or the recoveries of the separated sc pDNA
molecules [63].
On a similar approach, the successful results of amino acid li-
gands motivated Santos and their co-workers to explore L-trypto-
phan as a ligand [64]. The presence of aromatic ring side chain and
the rigid indole ring in L-tryptophan, contributes to its interactions
with the biomolecules like pDNA [65,66]. Based on this hypothesis,
L-tryptophan and its dipeptide derivatives (L-tryptophan-L-trypto-
phan and L-tryptophan-L-arginine) were investigated as afﬁnity li-
gands immobilized onto Sepharose CL-6B to separate sc pVAX-LacZ
and sc pPH600 from their oc isoforms. The separation took place
with decreasing in the concentration of ammonium sulphate from
2.65M to 0M in 100mM HEPES acid (pH7.4) at 10 C. The re-
searchers explained that the interaction between the ligands and
the pDNA depends on the hydrophobic interaction and p-p stack-
ing of 5-mononucleotides of pDNA with the L-tryptophan based
ligands. The investigation team successfully proved the puriﬁcation
efﬁciency of the L-tryptophan-Sepharose; this paves the way for
further investigations to implement these procedures directly on
the E.coli lysate [64]. In a parallel approach, naphthalene tripodal
was immobilized onto epoxy-activated Sepharose CL-6B, for the
ﬁrst time, to isolate sc pVAX1-LacZ [20]. The interaction between
the new ligand and the 50aminonucleotides was found to be hy-
drophobic and p-p stacking. Gradient increase in sodium chloride
concentration of the elution system from 95mM to 550mMat Tris-
HCl pH 8 at 4 C achieved the best separation. The presence of the
three amino acids in naphthalene tripodal promotes its interactions
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parison. Overall, the investigators provided a quick (two steps),
clean and low salt consumable method that can be used for puri-
ﬁcation of sc pVAX1-LacZ [20].
To conclude, Afﬁnity chromatography is a facile puriﬁcation tool,
which ascertained its feasibility in separation of pDNA. The versa-
tility of the ligands eases the task of the investigators to ﬁnd robust
and selective pDNA isolation methods. The afﬁnity
chromatography-isolated pDNAs demoed sufﬁcient purity and
appropriate recovery with small pDNA. However, incorporation of
ammonium sulphate in the elution systems might have harmful
environmental impacts. The researchers could develop novel
methods with low ammonium sulphate concentrations if needed.
Moreover, puriﬁcation of the large size pDNA molecules by afﬁnity
chromatography was not achieved in reasonable yields due to the
vigorous production and extraction procedures. Further investiga-
tion might be needed to improve the yield upon puriﬁcation of
large pDNA molecules.
3.5. Hydrophobic interaction chromatography (HIC)
Due to the differences in the hydrophobicity of the components
of the bacterial lysates, HIC gained a great attention as a puriﬁcation
tool of pDNA and pDNA isoforms [67]. Separation of pDNA by HIC
depends on the concentration of the salts in the mobile phase
buffer passing through a hydrophobic support. Thus, high salt
concentration enhances the interaction between the pDNA and the
hydrophobic support and vice versa [43]. HIC separations are per-
formed in four steps; equilibration, sample application, elution and
regeneration [68]. Equilibration step is to prepare the stationary
phase for separation by passing a buffer containing salt (usually
sodium phosphate or ammonium sulphate). Sample application
and wash step is put in place to introduce the sample into the
stationary phase and wash the weakly bound impurities by mod-
erate concentration of the salt. Elution stage is carried out by
gradient decrease of the salt concentration to separate the pDNA
isoforms. The ﬁnal step is the regeneration of the stationary phase,
to remove all the strongly bound molecules [68]. The conditions of
HIC are mild and “protein friendly” giving the advantage of the
excellent recoveries [69].
In 2013, Bonturi et al. tried to exchange the mobile phase salt of
the traditional HIC methods, from the hazardous ammonium sul-
phate to ecofriendly salts like sodium citrate or potassium phos-
phate in the separation of pVAX1GFP (3697 bp), from bacterial
lysates [70]. The mobile phases used are phenyl agarose adsorbent
(HIC support) and mercaptopyrimidine-agarose adsorbents (thio-
philic aromatic chromatography support). Themethodwas adapted
to be performed directly on the bacterial lysate without any pre-
liminary preparatory steps. The elution system containing 1.5M
sodium citrate with mercaptopyrimidine-agarose adsorbent
recovered 91.1% of pDNA [70]. Nevertheless, this elution system
obtained very low pDNA purity (13.4%), suggesting it to be a pre-
liminary puriﬁcation step because of its high recovery. While in a
single step, 2M potassium phosphate elution system with
mercaptopyrimidine-agarose column as well, recovered 68.5% of
pDNA with purity of 98.8%. Despite the low recovery, the exalted
purity of the obtained pDNA is enough to meet the international
vaccine purity recommendations. Moreover, the cleanness, cost
effectiveness and quickness of this method make it valid for
application as a single-step pDNA puriﬁcation method. However,
the separation between the pDNA isoforms is still invalid using this
method [70]. In order to provide a new cost effective single step HIC
for puriﬁcation of sc pDNA isoform, Bo's team conducted a research
[71]. The research team utilized Octyl Sepharose 4 Fast Flow
adsorbent as column packing material. The mobile phase used wasascending concentration of ammonium sulphate (from 2 to 3M) in
40mM Tris/HCl, at pH 8 using pCDNA3.1-GFP clariﬁed lysate as a
sample. The elution was monitored using agarose gel electropho-
resis and anion exchange HPLC. Puriﬁcation of sc pDNA was per-
formed with 98%± 1.2% purity and 75% recovery. Bo et al.’s method
is considered quick and simple tool for puriﬁcation of sc pDNA
directly from bacterial lysates; nevertheless, the use of ammonium
sulphate may limit this method because of its harmful effects [71].
In the same year, Limonta et al. tried to improve the productivity
and reduce the cost of production of HCV pDNA vaccine (pIDKE2)
through simulating the large scale puriﬁcation in a laboratory scale
[72]. The researchers used a newly design manufacturing technol-
ogy called Convective Interaction Media (CIM) technology on a lab
scale. CIM C4 HLD monolithic column was utilized and the sample
was washed by 25mmoL/L Tris-HCl (loading buffer) and then
eluted will 25mmoL/L Tris-HCl, 10mmoL/L EDTA pH 7.0. CIM
technology was found to be superior to the traditional beads media
in terms of cost (39% decrease in the cost), purity (94%) and re-
covery (80e90%), see Fig. 7 [72].
In 2014, Rocha et al. designed a study to evaluate the ability of
gellan gum (polysaccharide polymer) in separation of pDNA by HIC
on an analytical scale [73]. The stationary phase was prepared by
adding 2.5% (w/v) gellan and 90mM CaCl2 to 5% (v/v) DMF, and
then left at 90 C for 14 h. Separation trials of the sc isoform of pVAX
mixed with RNA sample were implemented using a two-step
elution. The ﬁrst step; 0.2M ammonium sulphate in MES buffer
and calcium chloride, and the second step; the salt was removed
from the elution system [73]. The resulted data showed that the
pDNA molecules retained at the ﬁrst step in the columnwhile RNA
and other impurities were eluted. While in the second elution step,
all the retained pDNA were liberated, as shown in Fig. 8. Thus,
gellan gum can be used as HIC stationary phase. However, more
trials are needed to check the feasibility of gellan gum in puriﬁca-
tion of sc pDNA from lysates [73].
In a novel approach, Üzek et al. used magnetic nanoparticles in
puriﬁcation of pDNA [74]. Emulsion polymerization technique was
used to produce magnetic nanoparticles and different elution sys-
tem conditions were implemented. The best separation took place
with elution system of an acetate buffer (pH: 5.5) consisting of
1.0M Na2SO4 at 40 C and magnetic nanoparticles of size 52.0 nm
and polydispersity index of 0.205 as stationary phase. The highest
adsorption capacity of the nanoparticles measured was 211.3mg/g.
This method succeeded in separation of oc pDNA from other iso-
forms and impurities [74]. Although, the oc pDNA is not beneﬁcial
for using in vaccines, this method proved the feasibility of using
magnetic nanoparticles in pDNA puriﬁcation because of their high
adsorption capacity to pDNA [74]. In 2015, Pyridine was immobi-
lized onto methacrylate monolith to purely separate sc pEGFP-N1.
Pyridine monolith was compared to C4HLD monolith using
descending ammonium sulphate as an elution system to ﬁnd that
both have the same dynamic binding capacity and recovery and the
same ability of separating impurities. However, pyridine-modiﬁed
monolith separated sc pDNA with better purity (98%) than C4HLD
(95%) [75].
3.6. Anion exchange chromatography (AEC)
The Anion exchange chromatography AEC is employed in puri-
ﬁcation of pDNA using positively charged stationary phases, taking
the advantage of the negatively charged phosphate groups of
pDNA. Although the lysate contains different topologies which may
have the similar overall charge and molecular weight, the differ-
ences of the conformations of the isoforms change the distribution
of the charge densities [15]. Thus, positively charged stationary
phases interact locally with the opposite charges of pDNA isoforms.
Fig. 7. Recovery of pIDKE2 plasmid using CIM C4 HLD matrix. Collected fractions were analysed by agarose 0.8% electrophoresis, (a) (1) initial sample, (2) not bound fraction, (3)
elution fraction, (4) regeneration; (b) chromatographic behavior of elution fraction analysed on CIMacTMpDNA-0.3 analytical column which contains 94%purity of pIDKE2 [72].
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will be separated according to the chain length of the molecules.
Longer chain length has more phosphate groups and then higher in
charge density [15]. Therefore, the supercoiling of the sc isoform
boosts the charge density over that of oc isoform. Accordingly, the
sc isoform tightly interacts with the positively charged stationary
phase ligand, allowing the sc isoform to elute after the oc isoform
[76]. Nevertheless, separation of linear pDNA is not just dependent
on the charge density, but also on its physicochemical character-
istics. For instance, small DNA fragments may take a coil shape in
solutions, which increase its elasticity and enhance its separation
from the sc and oc isoforms. Moreover, other interactions like,
dispersive forces, hydrogen bonding, dipole-dipole attraction and
solvophobic repulsion can also affect the separation by AEC. How-
ever, the non-speciﬁc binding of the anion exchange stationary
phases, affects the pDNA selectivity from other lysate components.
The need for appropriate purity of the obtained pDNA may require
the use of complementary puriﬁcation steps like size exclusion
chromatography or agarose gel electrophoresis [77,78].
In 2011, Zhong et al. aimed at removal of RNA impurities from
pDNA sample without using RNase by ﬁrstly, precipitation of pDNA
takes place with isopropanol as a pre-puriﬁcation step [79]. Sec-
ondly, anion exchange membrane chromatography wasimplemented to get rid of the RNA impurities. The stationary phase
is an anion exchange membrane incorporated with 3-
acrylamidopropyl-trimethylammonium chloride packed in stain-
less steel membrane disk holder. The elution system is a gradient
increase in sodium chloride concentration from 50mM NaCl in
Tris-HCl to 1M NaCl at pH 8. The recovery of pDNA is 84%. The
method is rapid, cheap and efﬁcient; however, it is not convenient
for separation of pDNA isoforms [79]. Aiming at puriﬁcation of large
pDNAmolecules (25 kbp), Ongkudon et al. innovated a new conical
monolith column employed in one step for this purpose, by
reducing the wall channel size of monolith column [42]. The whole
sample was diluted with buffer A (25mM TriseHCl, 2 mMEDTA, pH
7) and then washed by eluting buffer A: buffer B (25mM TriseHCl,
2mM EDTA, 1.0M NaCl, pH 7) (8:2) to remove the impurities and
ﬁnally elution was done by mixing buffer A with buffer B to elute
the pDNA. The mild conditions of the elution system allowed the
researchers to separate large size pDNA (25 kbp) in a reasonable
purity and recovery as shown in Fig. 9. Such large pDNA molecules
could not be separated in a good yield in drastic methods like af-
ﬁnity chromatographic methods. [42].
In 2015, Bicho et al. employed ion exchange chromatography for
puriﬁcation pDNA inﬂuenza vaccine. Ethylenediamine (EDA) was
used as a ligand immobilized into monolithic discs with
Fig. 8. Elution proﬁles obtained to the nucleic acid samples. The binding step was made in MES buffer (10mM, pH 6.2) with CaCl2 (90mM) and (NH4)2SO4 (2.5M) and the elution
step was made with MES buffer (10mM, pH 6.2) with CaCl2 (90mM). Black line and dashed lines represent the absorbance at 280 nm of the fractions and salt concentration,
respectively. (A) Obtained proﬁle to the RNA sample. (B) Obtained proﬁle to sc pDNA sample [73].
Fig. 9. Anion exchange chromatography of 25 kbp DNA using diethylamine-
functionalised polymethacrylate conical monolith. Buffer A (25mM TriseHCl, 2
mMEDTA, pH 7). Buffer B (25mM TriseHCl, 2mM EDTA, 1.0M NaCl, pH 7). Flow
rate:1.0mL/min; Sample: 1mL of clariﬁed alkaline lysed cell lysate. Dashed line:
AU(260 nm); solid line: %B [42].
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sample was pre-puriﬁed with Maxi Kit from Qiagen and then
loaded into the discs. Different salt concentrations were imple-
mented and the elution was monitored by UV at 260 nm. The
separated fractionswere analysed using agarose gel electrophoresis
and HPLC using CIMac™ pDNA analytical column. It was found that
the best separation takes place by gradient increase in NaCl from
1.65M to 1.85M in 50mM phosphate buffer at pH 7.5. The research
group explained this on the fact that sc pDNA is negatively charged
so it interacts with EDA. Low concentration of the salt (1.65M)
decreases the ionic strength of the mobile phase which keeps the
pDNA particles strongly attached to EDA and allows the non-pDNA
particles like oc plasmid, RNA molecules, gDNA, proteins and en-
dotoxins to separate [80]. By increasing the salt concentration to
1.85M, the ionic strength increases allowing the strongly bound
pDNA to liberate. The pDNA inﬂuenza vaccine was obtained with
97.1% purity and 47% yield. This method is ecofriendly; however, the
yield obtained is not satisfactory [80]. Recently, Frenco-Medrano
et al. carried out a comparative study between different column
packing materials of AEC using Mustang Q membranes andperfusive beads packed columns in separation of the leishmania
pDNA vaccine [81]. AEC membrane and perfusion bead puriﬁca-
tions were performed using 0.5 5 cm (0.08mL packed volume)
column packed with Mustang Q membranes -which contains
quaternary amines immobilized on its pores- or Poros 50 HQ beads
-which contains quaternized polyethyleneimine group-
respectively [81]. The columns were equilibrated with 0.5M NaCl
in TE buffer. The mobile phase used is NaCl in TE buffer where the
salt concentration increases gradually via 3 steps. The ﬁrst one is
from 0.6 to 0.725MNaCl, then from 0.725 to 1.1MNaCl, and the last
step concentration is 2M to restore the column. The analysis of
elution at AEC membranes proved that the pDNA was adsorbed on
the membranes and retained and was not affected by the ﬁrst and
the second elution steps. Increasing the ionic strength of the elution
system at the third step let the pDNA particles to exit from the
column at an acceptable yield (88%) [81]. Comparing to AEC
perfusion bead system, small pDNA particles can pass through the
pores of the perfusion beads and the adsorption on the beads is not
enough just to retain them. Part of the pDNA molecules exits the
column during the ﬁrst two steps of elution, so the yield of the
obtained pDNA declines to 63% [81].3.7. Multimodal chromatography (MMC)
The need of a single chromatographic procedure that exerts
more than one interactionwith the samples at the same time, led to
the invention of multimodal or mixed mode chromatography
(MMC). The MMC ligands have more than one active site that can
exhibit more than one type of interactions at the same conditions
[82]. For example, ligands possess a hydrophobic moiety and an
ionic moiety can be used in multimodal chromatography (MMC) to
exhibit multiple non-covalent interactions with the intended
molecules. This advantage allowed the scientist to use MMC in
various puriﬁcation applications of macromolecules and bio-
molecules including pDNA [22,83e85]. The recent studies revealed
different multimodal ligands like histamine [61] and agmatine [62]
for puriﬁcation of pDNA. Moreover, the MMC allows the investi-
gation group to use single chromatographic interaction as well,
A. Abdulrahman, A. Ghanem / Analytica Chimica Acta 1025 (2018) 41e5752depending on the mobile phase pH as shown in Fig. 10 [82]. For
instance, at low pH, the ionic moiety becomes protonated and
charged, so ionic chromatography takes place, thus, an anionic
elution system like NaCl solution should be used. At basic pH, the
ionic moiety becomes uncharged and the hydrophobic moiety's
effect dominates, hence, hydrophobic chromatography takes place,
and the elution system used should be hydrophobic like ammo-
nium sulphate solution [86].
Histamine was found to have multimodal properties as it shows
hydrophobic properties (imidazole ring), and ion-exchange char-
acter (amino group) [61]. Histamine's multimodal properties paid
the attention of Cernigoj and their co-workers, to be incorporated
into MMC as a ligand for separation of pJ plasmid (5.17 kbp) iso-
forms from clariﬁed E.coli strain HMS174 (DE3) lysate [61]. The
ligand (histamine) was immobilized onto monolithic CIM CDI col-
umn to take advantage of the promising mass transfer of monolith
column. The preliminary studies proved that, histamine demon-
strated reasonable dynamic binding capacity to pDNA which may
be related to the high base exposure and abundance of active sites
of histamine which allows it to interact with pDNA. The separation
of the sc pDNA isoformwas done through two steps using different
elution systems on the same column. In the ﬁrst step, an elution
system of ascending gradient of NaCl at acidic buffer was employed
to reveal the anion exchange properties of histamine ligand. In this
step, the separation of pDNA from other lysate contaminants took
place with 90% yield. After that, the obtained fractions was
repuriﬁed to separate the sc pDNA from oc pDNA using 3M
(NH4)2SO4 at descending pH gradient as a mobile phase on the
same column to obtain the sc pDNA isoformwith 97% yield and 98%
purity [61]. The research paper presents efﬁcient procedures for
puriﬁcation of sc pDNA; however, the high concentration of
ammonium sulphate in the elution system makes its application
costly and ecologically unclean [61]. Moreover, another research
group immobilized octylamine, combination of butyl (C4) grafted
methacrylate (gBuMA) and diethylaminoethyl (DEAE) onto meth-
acrylate monoliths aiming at puriﬁcation of pDNA to compare their
puriﬁcation efﬁciency to that of butyl (C4) and DEAE methacrylate
monoliths [87]. The dual interactive abilities of the octylamine and
(gBuMA) and (DEAE) ligands are referred to the existence of its
hydrophobic chain (like octyl, butyl, ethyl groups) or by its ionic
exchange moiety (like amino groups). Investigations proved that
octylamine and gBuMA þ DEAE monoliths have the best results in
terms of binding capacity under both hydrophobic and ion-Fig. 10. Multimodal chromatographic principle. The binding and elution strategy of a target
charged groups (adapted from Ref. [52]). (A) At pH 4.5 a target protein in a mobile phase w
decreasing the salt concentration, but still maintaining a low pH, the electrostatic part of bin
have the same charge as the ligand and be repelled by it and is therefore eluted [82].exchange conditions. Therefore, the experiment was focused on
these two columns. The elution system was employed in 4 steps;
starts with 0.6 M NaCl in 10 mM EDTA, 50 mM Tris-HCl, then 3 M
ammonium sulphate in 10 mM EDTA, 50 mM Tris-HCl, then 3 M
ammonium sulphate with 1 M NaCl in 10 mM EDTA, 50 mM Tris-
HCl, and ﬁnally 1 M NaCl in 10 mM EDTA, 50 mM Tris-HCl [87].
The obtained pDNA showed an acceptable purity with removal of
around 99% of the impurities, with about 80% recovery. When it is
compared to puriﬁcation by HIC then IXE, MMC found to be simpler
and easier as its exempted in one step; however, the loading sample
used in the last one is slightly lower. Both OA and gBuMA þ DEAE
monoliths could not separate oc and sc isoforms; however,
gBuMA þ DEAE monolith showed promising data that may need
further optimizations. Moreover, the high concentration of
ammonium sulphate (3 M) in the elution systemmay contribute to
ecological threats [87]. In 2014, Matos et al. used a novel multi-
modal resin called “Capto Adhere resin” immobilized with N-
benzyl ethanolamine as a stationary phase to separate pUC18
(2.686 Kbp) from E.coli extract [88]. Capto Adhere resin was found
to undergo ionic and hydrophobic interactions and can bind
strongly to nucleic acids with adequate dynamic binding capacity
(60 mg/mL). The mobile phase used was gradient increase in NaCl
concentration (from 1M to 2M) in 10mMTris-HCl (pH 8.0), to yield
highly pure pDNAwith high yield. The researchers tried to separate
the two isoforms of pDNA using a linear NaCl gradient; however,
the separationwas partial and the sc pDNA purity is low (70%) [88].
In 2016, Silva-Santos et al. continuesMatos et al. [88] procedures
to provide a feasible method for separation of pDNA isoforms (sc
pDNA and oc pDNA) from a pDNA extract consists of 45.8% sc to
54.2% oc isoforms [22]. The research team used Capto adhere resin
as well; however, this time the Capto adhere resinwas immobilized
with N-benzyl-N-methyl ethanolamine ligand. The N-benzyl-N-
methyl ethanolamine consists of three different interaction sites;
the amine group and the hydroxyl group undergo ionic in-
teractions, and the benzyl group undergoes hydrophobic interac-
tion. Two mobile phases were employed; mobile phase (A) is low-
salt buffer (A: 10mM Tris-HCl and 1mM EDTA-TE, pH 8) and mo-
bile phase (B) is high-salt buffer (B: 2MNaCl in TE, pH 8) with
gradient increase in NaCl concentration. The separation took place
basing on the fact that the superior charge density of the two
topoisomers (oc and sc) might allow them to interact with the
charged amino group of the ligand [22]. However, the “torsional
strain” of sc pDNA induces the interaction with the hydrophobicprotein to a chromatographic medium containing a ligand with both hydrophobic and
ith a high salt concentration is bound to the hydrophobic part of the ligand. (B) Upon
ding becomes the dominating force. (C) With a pH step increase to 7.0, the protein will
Fig. 11. Loading of a mixture of oc and sc pDNA (pEGFP) with sc pDNA homogeneityof
80% on different CIMac columns in buffers containing speciﬁc concentrations ofAS.-
Loading buffer: 50mM TRIS, 10mM EDTA, different concentrations of ammo-
niumsulfate (AS), pH 7.4. Elution buffer: 50mM TRIS, 10mM EDTA, pH 7.4; Q
(volumetricﬂow rate)¼ 0.5mL/min, _¼ 260 nm.Pyridine column: _ (oc pDNA)¼ 3.5
_g/mL, _ (sc pDNA)¼ 15 _g/mL, c (AS)¼ 2.0M.C4 HLD column: _ (oc pDNA)¼ 4.7 _g/
mL, _ (sc pDNA)¼ 19.8 _g/mL, c (AS)¼ 1.7M.Histamine column: _ (oc pDNA)¼ 4.6 _g/
mL, _ (sc pDNA)¼ 19.0 _g/mL, c(AS)¼ 2.1M [92].
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time than the oc isoform. The oc and sc isoforms were separated
with purity of 91.8% and 92.2%, respectively. This method can be a
complementary method for Matos et al. [88] work, which failed to
separate the two isoforms. However, the feasibility of application of
Silva-Santos et al. directly onto the bacterial lysates is still un-
proven. Moreover, the obtained pDNA purity doesn't comply to the
pharmaceutical recommendations [22]. In 2016, Bicho et al. per-
formed a research aiming at studying the versatility of agmatine as
a multimodal ligand for puriﬁcation of inﬂuenza sc isoform of
plasmid NTC7482-41H-VA2HA vaccine from E.coli lysate [86].
Agmatine can act as a multimodal ligand, since it has butyl group
(hydrophobic moiety) and amino group (ionizable group). Agma-
tine was ﬁrst immobilized into CDI monolith column. In order to
purify sc pDNA, the investigators tried two strategies of elution. The
ﬁrst one is gradual descending of ammonium sulphate from 3M to
0M at 50mM phosphate buffer at pH 9.6, and the second is gradual
ascending of sodium chloride from 1.28 to 2M at 50mM phosphate
buffer at pH 8. The Separation of sc pDNA was successfully done
with 98.3% purity and 51.8% recovery with ammonium sulphate
elution system. While separation of pDNA took place with 99.6%
purity and 45.3% recovery with sodium chloride elution system
[86]. Bicho et al. and their team provided the literature with one-
step puriﬁcation method of sc isoform; however, the procedures
require elevated salt concentrations which make it costly and
ecologically unsafe. Moreover, the recovery of sc isoform is low
[86]. Recently, Silva-Santos et al. [89] tried to optimize their pre-
vious method [22] to isolate sc pDNA using the same stationary
phase (CaptoTM adhere) immobilized with N- benzyl-N-methyl
ethanolamine. This time the sample was prepuriﬁed by precipita-
tion with isopropanol then precipitation with ammonium acetate
and polyethylene glycol (PEG). The obtained fractions were puriﬁed
using CaptoTM adhere to isolate sc pDNA. The elution system used
was a gradual increase of NaCl concentration in 10mM Tris-HCl,
1mM EDTA, pH 8 buffer. At the beginning, a concentration of
830mM NaCl in the buffer solution was applied as a mobile phase
to elute oc pDNA. Then, the NaCl concentration was elevated to
920mM to liberate sc pDNA. Finally, 2M NaCl was applied to
remove RNA fractions [89]. The method could achieve baseline
separation of the three components, indicating a good separation.
In order to measure the reproducibility of the method, different
sized pDNA molecules [pVAX1-GFP (3696 bp), pUC18 (2687 bp)
and pCEP4 (10,410 bp)] were used. The method achieved repro-
ducible results with baseline separation of the pDNA isoforms of
the three different pDNA molecules. The researchers tried to purify
the pDNA molecules directly after isopropanol precipitation,
bypassing the ammonium acetate and PEG precipitation; however,
the protein content was found to be higher in the sc fraction which
affects the lifetime of the resin [89]. The method is ecofriendly and
cost effective as the researchers used low concentrations of NaCl
and avoided using ammonium sulphate. Moreover, the yield of the
sc and oc pDNA from the multimodal chromatography step is 83%,
with ﬁnal chromatographic puriﬁcation process yielded sc-rich
fractions (>90%) that contains low levels of gDNA and protein im-
purities. However; the whole puriﬁcation process could yield only
47% pDNA (oc and sc isoforms) [89].
3.8. Sample displacement chromatography (SDC)
Displacement chromatography is a chromatographic method
where the sample is ﬁrstly introduced to the column and then
displaced by a stronger sorbed solute [90]. Thus, the sample com-
ponents are separated into successive rectangular zones, allowing
the separation of the sample ingredients in high purity. Displace-
ment chromatography columns are usually used as preparativecolumns as they offer a reliable method to obtain the desired
component with high concentration, purity and yield specially with
biomolecules [90]. Separation in displacement chromatography
depends on the availability of unoccupied active sites of the sta-
tionary phase molecules. Separation takes place through three
stages; loading stage, displacement stage and regeneration stage. In
the loading stage, the biomolecules are introduced into the column
to occupy all the stationary phase's active sites and equilibrium
takes place [91]. The next stage is the displacement stage, where a
solute (displacer) of a higher afﬁnity than the biomolecule is
introduced in order to compete with the biomolecule on the active
sites of the stationary phase. Thus, the displacer expels the bio-
molecules to the mobile phase in a high concentration and high
purity. The last stage is the regeneration stage, where the displacer
is removed by means of washing with organic solvent, large
changes in the pH or chemical reaction [91].
In 2015, Cernigoj et al. puriﬁed sc pDNA by SDC as a novel
technique [92]. In this technique sc pDNA isoform is the displacer of
oc and linear pDNA. CIM monolith was used as stationary phase
because of its sufﬁcient mass transfer efﬁciency. The researchers
compared the separation efﬁcacy by different CIM monolith col-
umns loaded with different molecules of different hydrophobicities
(CIM C4 HLD, CIM-histamine and CIM-pyridine) as illustrated in
Fig. 11 [92]. It was concluded that the efﬁciency of sample
displacement depends on the selectivity of the column of a single
isoform, column efﬁciency and concentration of ammonium sul-
phate in the loading buffer. The method can be a valuable approach
for preparative scale because it needs lower concentrations of
ammonium sulphate and the obtained pDNA showed acceptable
purity [92].3.9. Miscellaneous chromatographic methods
As was stated in our 2013 review, puriﬁcation can be done by
single or multiple chromatographic steps [15]. Size exclusion
chromatography is still usually employed as a polishing step fol-
lowed other chromatographic procedures. In 2013, Sun et al.
Fig. 12. Mini Q analysis of plasmid DNA containing solutions collected throughout the puriﬁcation process: (a) clariﬁed lysate, (b) TFF retentate, (c) IEC (Q Sepharose XL) peak II and
(d) HIC (Phenyl Sepharose 6 FF) peak I. Using the Mini Q analytical column, plasmid DNAwas eluted with a NaCl gradient to 1.0M in 50mM sodium phosphate buffer at pH 7.0. The
dilution factors of the samples (100mL) injected were 1:10, 1:100, 1:100 and 1:100, respectively. UV absorbance at 260 nm was used to monitor the chromatography runs [23].
A. Abdulrahman, A. Ghanem / Analytica Chimica Acta 1025 (2018) 41e5754presented a large scale method of pDNA puriﬁcation by tangential
ﬂow ﬁltration, and multistep chromatography using AEC, HIC then
size exclusion chromatography [23]. Tangential ﬂow ﬁltration of
lysate was to eliminate RNA by pressurizing the lysate at 10e15 psi
through Centrasette TFF cassette with a polyether sulfone (PES)
membrane and then dialysis against 0.5M KAc, pH 5.5. The second
step is ion exchange chromatography using Q Sepharose XL resin as
stationary phase and the elution system was processed via two
steps, the ﬁrst one is 0.6M NaCl, 50mM Tris-HCl, 10mM EDTA, pH
8.0 to remove the remaining RNA and the second step in 1.0M NaCl
at the same buffer to elute the pDNA. The eluted solution was
concentrated and loaded onto hydrophobic interaction column
(Phenyl Sepharose 6 FF). The elution was achieved by decreasing
concentration of ammonium sulphate from 2M to 0M at 50mM
Tris-HCl, 10mM EDTA, pH 8.0 [23]. The third puriﬁcation step used
was size exclusion chromatography by passing the last eluted
sample through column packed with 5.5 L Sepharose 6 FF resin
with elution system of 20mM PBS, pH 7.2. The last fraction was
sterilized, concentrated and analysed using agar gel electropho-
resis. The product resulted was pure enough to meet the pharma-
ceutical grade requirements with minimum amount of impurities.
A two kilograms of bacterial cell paste yielded 800mg of pDNAwith
overall yield 48%with nearly 100% purity. TheMini Q analysis of the
four steps is shown at Fig. 12 [23].
4. Conclusion
The puriﬁcation step is the key step in pDNA vaccines produc-
tion. The purity of the pDNA vaccine can affect its efﬁcacy andstability. Thus, the regulatory bodies oblige the manufacturers to
prepare the pDNA vaccines in certain purity that can achieve the
best efﬁcacy and stability. The instability of the pDNA towards
temperature, pH and mobile phase salt concentration is the main
hurdle facing researchers during their puriﬁcation trials. Over the
last ﬁve years, many research teams exerted their efforts on puri-
ﬁcation of pDNA especially the sc isoform using chromatography.
The last few years witnessed a change in scholars' heed in puriﬁ-
cation of pDNA vaccines. Size exclusion and reversed phase chro-
matography are no longer used as a single puriﬁcation step. Both
are generally employed mixed with other chromatographic mo-
dalities. In comparing to our review in 2013 [15], there is an
increasing interest in afﬁnity chromatography for the puriﬁcation
of pDNAvaccines in the last ﬁve years. This may be attributed to the
high selectivity and speciﬁcity of afﬁnity chromatography [46].
However, the deteriorating effect of salts and pH used limits its use
in separation of large size pDNAs. Furthermore, AEC is still of
concern of many researchers in isolation of pDNA; however, it is no
longer the predominant chromatographic method as was viewed
previously in 2013. In addition, the hydrophobic properties of pDNA
allowed the scholars to enrich the literature with separation
methods via HIC. Moreover, the promising chromatographic mo-
dality; MMC, started to attract many research teams as a puriﬁca-
tion tool of pDNA during the last few years which was not common
before 2013. On the other hand, some chromatographic techniques
have declined; for example, tentacle chromatography. The latter is
one of the techniques that has not been well explored. Further-
more, expanded bed chromatography did not attract research
groups in the last ﬁve years due to its limited loading capacity [15].
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considered a new promising approach. Although the preliminary
studies showed an acceptable degree of pDNA purity that qualiﬁes
this technique to be used in the industrial scale, puriﬁcation of
pDNA by SDC technique is still not well investigated.
The advantages of Convective Interaction Media (CIM) monolith
stationary phases, including low backpressure and quick separation
of macromolecules, qualiﬁed them to be used effectively in sepa-
ration of pDNA. CIMmonolith stationary phases enabled them to be
implemented in different chromatographic modalities including
afﬁnity, hydrophobic interaction, anion exchange and multimodal
chromatographies. As it was predicted in our last review, methac-
rylate monolith has proved its efﬁcacy in puriﬁcation of pDNA due
to its outstanding productivity. The low back pressure of the
methacrylate monolith columns, allowed the researchers to use the
same columns in the small and the large scales. This assists the
investigators to explore the column's industrial behavior in the
laboratory giving a deep insight on their industrial application.
Although scientists have achieved a notable success in the ﬁeld
of puriﬁcation of pDNA vaccines, more investigations are still
needed to be carried out. The clariﬁcation and pre-puriﬁcation
steps may affect the yield obtained after puriﬁcation. Thus, the
need of a single chromatographic step that allows the separation of
pDNA in an adequate purity and yield without a clariﬁcation or pre-
puriﬁcation step is still not well investigated. Moreover, the envi-
ronmental considerations should be taken into account while
choosing the elution salt. The use of hazardous salts should be
avoided and replaced with ecofriendly cheap salts like sodium
chloride. Furthermore, more efforts should be exerted for separa-
tion of labile large pDNA molecules that can be affected by pH and
salt concentration of the mobile phases.References
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